

Claims

1. Use of Riluzole or a pharmaceutically acceptable salt thereof if desired with appropriate adjuvants and additives for the production of a medicament for the therapy or prevention of a diseased characterized by hyperproliferation of keratinocytes and/or T cells.
2. Use according to claim 1, characterized in that the disease is selected from psoriasis, atopic dermatitis, actinic keratosis, hyperkeratosis like epidermolytic hyperkeratosis, hyperkeratosis lenticularis perstans, keratosis pilaris and ichthyoses.
3. Use according to claim 1, characterized in that the diseased is selected from the group consisting of alopecia areata, alopecia totalis, alopecia subtotalis, alopecia universalis, alopecia diffusa, atopic dermatitis, lupus erythematodes of the skin, lichen planus, dermatomyositis of the skin, atopic eczema, atopic dermatitis morphea, scleroderma, psoriasis vulgaris, psoriasis capitis, psoriasis guttata, psoriasis inversa, alopecia areata Ophiasis type, androgenic alopecia, allergic contact dermatitis, irritative contact dermatitis, contact dermatitis, pemphigus vulgaris, pemphigus foliaceus, pemphigus vegetans, scarring mucous membrane pemphigoid, bullous pemphigoid, mucous membrane pemphigoid, dermatitis, dermatitis herpetiformis Duhring, urticaria, necrobiosis lipoidica, erythema nodosum, lichen vidal, prurigo simplex, prurigo nodularis, prurigo acuta, linear IgA dermatosis, polymorphic light dermatosis, erythema solaris, lichen sclerosus et atrophicans, exanthema of the skin, drug exanthema, purpura chronica progressiva, dihidrotic eczema, eczema, fixed drug exanthema, photoallergic skin reaction, lichen simplex periorale dermatitis, graft-versus-host-disease, acne, abnormal scarring keloids and vitiligo.
4. Use according to one of claims 1 to 3, characterized in that the medicament is applied topically.
5. Use according to claim 4, characterized in that the medicament is formulated in the form an ointment, a gel, a band-aid, an emulsion, a lotion, a foam, a cream of a mixed phase or an amphiphilic emulsion system (oil/water-water/oil-mixed phase), a liposome, a transfosome, a paste or a powder.

6. Use according to claim 5, characterized in that the cream is cream basis DAC (Deutscher Arzneimittel Codex (DAC Basiscreme)).
7. Use according to one of claims 1 to 6, characterized in that Riluzole or a pharmaceutical acceptable salt thereof is comprised within the medicament in a concentration based on the weight of the total formulation of between 0,01%-10% Riluzole, preferably between 0,1%-8% Riluzole, even more preferred between 1% and 4% Riluzole.
8. Use according to one of claims 1 to 7, characterized in that Riluzole or a pharmaceutical acceptable salt thereof is comprised within the medicament in a concentration of between 1 μ mol/l and 100 mmol/l.
9. Composition comprising Riluzole or a pharmaceutical acceptably salt thereof and one or more active ingredients, which decrease or inhibit the hyperproliferation of keratinocytes and/or T cells.
10. Composition according to claim 7, characterized in that the active ingredient is selected from group consisting of vitamin D derivates, as agonists of vitamin D receptors, in particular Calcipotriol, retinoid derivatives as agonists of retinoid receptors (RAR), in particular tazarotene, corticosteroid derivatives of glucocorticoid receptors, in particular betamethasone and cortisone, fumaric acid, skin thinning agents, in particular clobetasol, antagonist of TNF alpha, antagonists of dihydrofolate-dehydrogenase, in particular methotrexate and immuno-suppressive substances like, for example, amphotericin, busulfan, cotrimoxazole, chlorambucil, colony stimulating factor, cyclophosphamide, fluconazole, ganciclovir, anti-lymphocyte immunoglobulins, regular immunoglobulins, methylprednisolone, octreotide, oxpentifylline, thalidomide, zolimomab aritox and clotrimazole.
11. Composition comprising Riluzole or a pharmaceutical acceptably salt thereof and one or more calcineurin antagonist(s).
12. Composition according to claim 9, wherein the calcineurin antagonist is selected from cyclosporine A, cyclosporine G, cyclosporine B, cyclosporine C, cyclosporine D, dihydrocyclosporine D, Cyclosporine E, cyclosporine F, cyclosporine H, cyclosporine I, ASM-240,

pimecrolimus, tacrolimus, 13-desmethyl derivatives of tacrolimus and/or 17-ethyl-derivatives of tacrolimus.

13. Use of a composition according to one of claims 7-10, if needed with suitable adjuvants and additives for the production of a medicament for the therapy or the prevention of diseases characterized by hyperproliferation of keratinocytes and/or T cells.
14. Topical medicament for transdermal delivery comprising Riluzole or a pharmaceutical acceptable salt thereof and a topical excipient, characterized in that no significant amount of a dermal penetration enhancer is present.
15. Topical medicament for transdermal delivery, characterized in that the topical excipient is selected from the group consisting of an emulsion, a gel, an ointment, a foam, a band-aid, a cream of a mixed-phase and amphiphilic, respectively emulsion system (oil/water-water/oil-mixed-phase), a liposome or transfersome.
16. Topical medicament according to claim 14 or 15, characterized in that the topical excipient is cream basis DAC..
17. Topical medicament according to claims 14 to 16, characterized in that Riluzole or a pharmaceutical acceptable salt thereof is comprised within the medicament based on the weight of the total formulation in a concentration of between 0.01%-10% Riluzole, preferably between 0.1%-8% Riluzole, even more preferred between 1% and 4% Riluzole.
18. Topical medicament according to claims 14 to 17, characterized in that the medicament further comprises a compound selected from the group consisting of selegiline, selegeline in combination with tocopherol; levodopa; bromocriptine; bromocriptine; trihexyphenidyl; trihexyphenidyl; amantadine; botulinum toxin type A; tizanidine; dantrolene sodium; baclofen, benzodiazepines, preferably diazepam or clonazepam; cloniodine; gabapentin; lamotrigine; cyproheptadine; cannabinoid-like compounds; fluoxetine; paroxetine; sertraline; fluvoxamine; citalopram; escitalopram, St. John's wort; enlafaxine; bupropion; nefazodone; mirtazapine; trazodone; tricyclic antidepressants, preferably amitriptyline, nortriptyline, desipramine, clomipramine, doxepin, protriptyline, trimipramine, or imipramine; MAO-inhibitors, preferably phenelzine or tranylcypromine; anticholinergic agents, preferably benztrapine, pro-

cyclidine, diphenhydramine, clozapine, olanzapine, risperidone, quetiapine, ziprasidone, topiramate, tiagabine, oxacarbazepine, phenytoin, carbamazepine, fosphenytoin, zonisamide, clobazam, clonazepam, phenobarbital, primidone, vigabatrin, valproate, felbamate, levetiracetam, barbiturates, imidazopyridine; antihistamines, preferably doxylamine; piperidines, preferably glutethimide or methyprylon; ethchlorvynol; chloral derivatives, preferably chloral hydrate and carbamates, preferably meprobamate.

19. Use of Riluzole or a pharmaceutical acceptable salt thereof for the preparation of a topical medicament for the therapy and/or prevention of neuronal or brain diseases and/or injuries.
20. Use according to claim 18, characterized in that the neuronal or brain diseases and/or injuries selected from Parkinson's disease, adrenoleukodystrophy, Dyskenesias, motoneuron diseases like spinal muscular atrophy, and infantile muscular atrophy, amyotrophic lateral sclerosis (ALS), primary lateral sclerosis, for disease states where anticonvulsant, anxiolytic or hypnotic activity is needed, schizophrenia, sleep disorders and depression, cerebrovascular disorders and suppressing pain, spinal, cranial or craniospinal traumas, damages by radiation, parkinsonian syndrome, neuro-AIDS, mitochondrial diseases, cerebellar dysfunction, acoustic traumas, especially deafness and tinnitus, spasticity, especially pyramidal spasticity, reduction of spinal cord injury induced by aortic cross-clamping.
21. Use of Riluzole or a pharmaceutical acceptable salt thereof and cream basis DAC for the preparation of a topical medicament for the treatment and/or prevention of skin disorders, especially psoriasis, atopic dermatitis, alopecia areata, alopecia totalis, alopecia subtotalis, alopecia universalis, alopecia diffusa, lupus erythematoses of the skin, lichen planus, dermatomyostis of the skin, atopic eczema, morphea, sklerodermia, psoriasis vulgaris, psoriasis capitis, psoriasis guttata, psoriasis inversa, alopecia areata ophiasis-type, androgenetic alopecia, allergic contact eczema, irritative contact eczema, contact eczema, pemphigus vulgaris, pemphigus foliaceus, pemphigus vegetans, scarring mucosal pemphigoid, bullous pemphigoid, mucous pemphigoid, dermatitis, dermatitis herpetiformis duhring, urticaria, necrobiosis lipoidica, erythema nodosum, lichen vidal, prurigo simplex, prurigo nodularis, prurigo acuta, linear IgA dermatosis, polymorphic light dermatoses, erythema solaris, lichen sclerosus et atrophicans, exanthema of the skin, drug exanthema, purpura chronica progressiva, dihidrotic eczema, Eczema, fixed drug exanthema, photoallergic skin reaction, lichen

simplex eriorale, dermatitis, "Graft versus Host-Disease", acne, rosacea, abnormal scarring, keloids and vitiligo.

22. Use according to claim 20, wherein the disease is selected from psoriasis or atopic dermatitis, especially psoriasis.